IcoSema

DRUG5 trials

Sponsors

Novo Nordisk A/S

Conditions

Diabetes Mellitus, Type 2Type 2 Diabetes

Phase 1

A Research Study to Look at How Insulin Icodec and Semaglutide Work in the Body of People From China With Type 2 Diabetes When Given Alone or Together

CompletedNCT05435677

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-06-22End: 2023-04-25Updated: 2025-03-21

Phase 3

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)

CompletedNCT05013229

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2021-11-30End: 2023-11-14Updated: 2025-12-02

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

CompletedNCT05259033

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-04-11End: 2024-01-16Updated: 2026-06-12

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

CompletedNCT05352815

Novo Nordisk A/SDiabetes Mellitus, Type 2

Start: 2022-06-01End: 2024-04-23Updated: 2025-12-04

A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)

CompletedNCT06269107

Novo Nordisk A/SType 2 Diabetes

Start: 2024-02-15End: 2025-07-08Updated: 2026-06-05

Related Papers

Efficacy and Hypoglycaemia Outcomes With Once‐Weekly <scp>IcoSema</scp> Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A <i>Post Hoc</i> Analysis of the <scp>COMBINE</scp> 1–3 Trials

Diabetes Obesity and Metabolism2026-08-05

Pharmacokinetic Characteristics of a Once-Weekly Combination Therapy of Insulin Icodec and Semaglutide Versus Its Separate Components in Chinese Individuals with Type 2 Diabetes.

2025-10-06

Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial.

2025-06-048 citations

Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial.

2025-06-046 citations

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial.

2025-01-179 citations

Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus

Clinical Drug Investigation2024-11-019 citations